Nanko, Raymond

Nanko, Raymond was paid $104K by Medicaid between Jan 2018 and Feb 2024, across 7 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 66% of everything it billed.

33Billing provider infoNANKO, RAYMOND
MUNCIE, IN 47305

33aNPI1497782932assigned 06/28/2006

33bProvider typeInterventional Pain Medicine Physician

28Total paid$104K

24GClaims7,743

24DCodes billed7

24AFirst – last monthJan 2018 – Feb 2024

Compared with peers

Next to other Interventional Pain Medicine Physician providers in Indiana

Rank by total paid#4 of 17

Median peer was paid$3K

This provider vs. median33×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	3,672	$30K
2019	1,244	$23K
2020	1,098	$14K
2021	866	$11K
2022	530	$14K
2023	301	$10K
2024incomplete	32	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	66%	2,892	2,131	$68K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	27%	1,134	894	$28K
80306		4.2%	893	674	$4K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	2.4%	1,070	867	$2K
82570		<1%	578	448	$539.29
81003		<1%	577	447	$491.61
84311		<1%	599	465	$47.20

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.